(Paris, France, Thursday, 18 September 2025) Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.
The study – the largest of its kind and presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 – also found that GLP1RAs significantly reduced the risk of alcohol abuse by 65% and substance abuse by nearly 50%.